skip to main content

    Updated Visitor Guidelines

 

MENU

 

Esophageal Cancer Team Members

The University of Michigan Rogel Cancer Center is provides a comprehensive, team approach to cancer specialty care. Although a patient may not see each member of the team, all of the specialists listed below are involved in reviewing patients’ cases and recommending a treatment plan that is tailored to the each patient.

Surgeons

Study available at U-M evaluates reparixin in combination with paclitaxel for metastatic triple-negative breast cancer

Triple-negative is the most aggressive kind of breast cancer. Triple negative tumors are negative for estrogen receptor, progesterone receptor and the HER2 protein. Because treatments that target these proteins would not work in triple negative breast cancer, the main treatment for it is chemotherapy.

Education and Training

Fellows, postdocs and trainees are critical to the success of the Rogel Cancer Center’s research programs.

male researcher uses a pipette in a lab

Family and Faith

The information on this page has expired. To learn about supporting the University of Michigan, please visit the Leaders and Best website.

Funding Opportunities

For the benefit of our research members, internal and external funding opportunities are posted and updated weekly. Any questions regarding these opportunities can be directed to Luke Brown [email protected]).

What are the benefits and harms of cancer screening? Most guidelines don’t tell you

A new study finds most cancer screening guidelines do not clearly spell out the benefits and harms of the recommended actions.

Study suggests many women with early breast cancer receive unnecessary imaging tests

A new study suggests that up to 60 percent of the CT scans, bone scans, and PET scans performed for more than 29,000 Michigan women diagnosed with early breast cancer between 2008 and 2014 could not be medically justified based on retrospective record review.

Pages